Liminatus Pharma (LIMN) vs Lunai Bioworks (LNAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lunai Bioworks is the larger company by market cap ($5.1 million vs $5.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | LNAI |
|---|---|---|
| Share price | $3.69 | $1.12 |
| Market cap | $4.96M | $5.08M |
| 1-day change | -4.65% | +2.75% |
| EPS (TTM) | $-23.50 | $-63.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $13.28 |
| 52-week low | $3.29 | $1.08 |
| Distance from 52-week high | -97.39% | -91.57% |
| Average volume | 453.28K | 181.21K |
| Shares outstanding | 1.34M | 4.53M |
| Employees | 1 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Healthcare · Biotechnology · 1 employees
About Lunai Bioworks
LNAI stock →Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC.
Healthcare · Biotechnology · 29 employees
LIMN vs LNAI FAQ
Which is bigger, Liminatus Pharma or Lunai Bioworks?
Lunai Bioworks (LNAI) is larger, with a market capitalization of $5.08M compared with $4.96M for Liminatus Pharma (LIMN).
Are Liminatus Pharma and Lunai Bioworks in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.